CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 17 enrolled
Drug / intervention
VRC-HIVADV027-00-VP +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00472719
NCT00472719Phase 1Completed
CompareCT.gov

A Phase 1B Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenoviral Serotype 35 (rAd35) and Serotype 5 (rAd5) HIV-1 Vaccines When Given in Heterologous Prime-Boost Regimens or as a Boost to a Recombinant DNA Vaccine in Healthy, HIV-1-Uninfected Adult Participants With Pre-Existing Immunity to Adenovirus Serotype 5 Infection

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted May 14, 2007·Updated Oct 14, 2021

In Brief

A Phase 1 clinical trial evaluating VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP, and 1 other intervention for HIV Infections. Completed, enrolled 17 participants across 7 sites.

Detailed Summary

The purpose of this study is to determine the safety of and immune response to an experimental DNA HIV vaccine followed by boosting with either an experimental adenoviral vector HIV vaccine of serotype 5 or 35 in HIV uninfected adults. This study will also determine the safety of and immune response to an adenoviral vector HIV vaccine of serotype 5 followed by a booster of an adenoviral vector of serotype 35, or vice versa, in HIV uninfected adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsHIV Vaccine Trials Network

Timeline

Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 14, 2007
Enrollment StartAug 1, 2007
Primary CompletionJul 1, 2008
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.1 years ago

Interventions

VRC-HIVADV027-00-VPbiological

Adenoviral vector booster vaccine

VRC-HIVADV038-00-VPbiological

Adenovirus vector booster vaccine

VRC-HIVDNA044-00-VPbiological

Experimental, multiclade, multigene HIV DNA vaccine